Page 173 - Binder2

You’re educating it.

This has profound implications for chronic autoimmune
conditions, inflammatory disorders, and allergic diseases.
Instead of provoking immune surveillance—as IV biologics
often do—edible therapeutics may induce tolerance,
reduce anti-drug antibody formation, and teach the immune
system to ignore the therapeutic rather than reject it.

This isn’t just a delivery upgrade.

It’s a design shift, one that aligns with how the immune
system evolved to interact with proteins.

Why Now? The Forces Driving Adoption

The moment for edible biologics isn’t just scientific—it’s
strategic.

• Post-pandemic decentralization has shattered the
assumption that all drugs must be delivered in
hospitals or infusion centers. The global system
now values what’s stable, ambient, and patient-
controlled.
• Payer pressure has escalated. With the average
cost of biologics exceeding $100,000 per year in
some cases, insurers are pushing back on injectable
maintenance therapies that don’t deliver sustained
benefit or require complex administration.
• Global access gaps remain stubbornly wide. In
much of the world, refrigerated drugs, IV infusions,
and specialist facilities are simply not accessible.
Edible biologics—grown locally, stored ambiently,
and taken orally—change that equation.

171